Potential Primary Endpoint for Exploratory Clinical Trial in Patients with Overactive Bladder: A Systematic Literature Review

被引:1
作者
Iino, Shingo [1 ]
Kaneko, Masayuki [1 ]
Narukawa, Mamoru [1 ]
机构
[1] Kitasato Univ, Dept Clin Med Pharmaceut Med, Grad Sch Pharmaceut Sci, Tokyo, Japan
关键词
endpoint; overactive bladder; randomized controlled trial; systematic literature review; PLACEBO-CONTROLLED TRIAL; ANTIMUSCARINIC AGENT SOLIFENACIN; TOLTERODINE EXTENDED-RELEASE; PROPIVERINE-CONTROLLED TRIAL; DOUBLE-BLIND; JAPANESE PATIENTS; PHASE-II; BETA(3)-ADRENOCEPTOR AGONIST; URGE INCONTINENCE; PARALLEL-GROUP;
D O I
10.1111/luts.12141
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
ObjectivesTo identify a potential primary endpoint in an early-phase exploratory trial among key overactive bladder (OAB) symptoms. MethodsPlacebo-controlled double-blinding trials in patients with OAB were extracted for systematic literature review. The correlation between key OAB symptoms recorded in bladder diaries and coefficient of variation (CV) in each study were assessed. ResultsForty-one controlled trials were extracted for the present review. Mean number of urgency episodes in 24 h was substantially associated with mean number of urgency incontinence episodes in 24 h, mean volume voided per micturition, and mean number of micturitions in 24 h (Spearman's r = 0.725, -0.661, and 0.657, respectively). Mean number of micturitions in 24 h was also substantially associated with mean volume voided per micturition (Spearman's r = -0.674). Mean number of incontinence episodes in 24 h was substantially associated with mean number of urgency incontinence episodes in 24 h and mean volume voided per micturition (Spearman's r = 0.840 and -0.628, respectively). The median CV of mean volume voided per micturition in each trial was the smallest among all endpoints. ConclusionsOur findings suggest that volume voided per micturition is a useful symptom for evaluating OAB candidate compounds in a small sample size and represents an effective primary endpoint, especially in exploratory clinical trials.
引用
收藏
页码:64 / 75
页数:12
相关论文
共 69 条
[1]  
Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
[2]  
[Anonymous], 2000, CLINICALTRIALSGOV IN
[3]  
[Anonymous], R LANG ENV STAT COMP
[4]  
Astellas Pharma Inc, 2000, CLINICALTRIALSGOV
[5]   A review of adherence to drug therapy in patients with overactive bladder [J].
Basra, Ramandeep K. ;
Wagg, Adrian ;
Chapple, Christopher ;
Cardozo, Linda ;
Castro-Diaz, David ;
Pons, Montserrat Espuna ;
Kirby, Mike ;
Milsom, Ian ;
Vierhout, Mark ;
Van Kerrebroeck, Philip ;
Kelleher, Con .
BJU INTERNATIONAL, 2008, 102 (07) :774-779
[6]   Randomized, double-blind placebo-controlled trial with Bryophyllum pinnatum versus placebo for the treatment of overactive bladder in postmenopausal women [J].
Betschart, Cornelia ;
von Mandach, Ursula ;
Seifert, Burkhardt ;
Scheiner, David ;
Perucchini, Daniele ;
Fink, Daniel ;
Geissbuehler, Verena .
PHYTOMEDICINE, 2013, 20 (3-4) :351-358
[7]  
Bryant Charmaine M, 2002, Br J Nurs, V11, P560
[8]   Efficacy and Adverse Events of Antimuscarinics for Treating Overactive Bladder: Network Meta-analyses [J].
Buser, Nora ;
Ivic, Sandra ;
Kessler, Thomas M. ;
Kessels, Alfons G. H. ;
Bachmann, Lucas M. .
EUROPEAN UROLOGY, 2012, 62 (06) :1040-1060
[9]   Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder [J].
Cardozo, L ;
Lisec, M ;
Millard, R ;
Trip, OV ;
Kuzmin, I ;
Drogendijk, TE ;
Huang, M ;
Ridder, AM .
JOURNAL OF UROLOGY, 2004, 172 (05) :1919-1924
[10]   Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms [J].
Chancellor, M ;
Freedman, S ;
Mitcheson, HD ;
Antoci, J ;
Primus, G ;
Wein, A .
CLINICAL DRUG INVESTIGATION, 2000, 19 (02) :83-91